[en] With new drugs being introduced to treat asthma it is timely to review criteria that can be used to assess efficacy in clinical trials. Anti-asthma drugs are classified into symptoms-modifying, symptom preventers and disease modifying agents. Attention is drawn to the types of experimental evidence required in preclinical studies to support further clinical development of a new therapy. Clinical trials demand careful selection of patients to maximise the strength of the efficacy signal according to the type of trial being designed. While provocation tests are useful in suggesting efficacy, negative tests do not necessarily indicate lack of anti-asthma activity. Therapeutic trial designs need to take account of duration of treatment, dose-response relationships and confirmatory trials. Outcome measures include symptoms, lung function, reduction in concomitant medication, exacerbations, quality of life and measures of inflammation. Interpretation of results need to include the clinical relevance of any changes as well as statistical significance. Special consideration needs to be given to the evaluation of drugs for acute severe asthma, asthma in children and older people, co-morbidity such as rhinitis, and inhaler devices. As with all drugs introduced into practice, careful attention needs to be paid to both short- and long-term safety. (C) 2004 Elsevier Ltd. All rights reserved.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Holgate, S. T.
Bousquet, J.
Chung, K. F.
Bisgaard, H.
Pauwels, R.
Fabbri, L.
Rabe, K.
Doherty, M.
Snell, N. J. C.
Cuss, F.
D'Amato, M.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
Summary of recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthma
Holgate ST, Davies DE, Lackie PM, Wilson SJ, Puddicombe SM, Lordan JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000;105:193-204.
Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720-45.
Global Initiative for Asthma. Global strategy for asthma management and prevention. National Institutes of Health, National Heart, Lung and Blood Institute (Available from www.ginasthma.com).
Leong KP, Huston DP. Understanding the pathogenesis of allergic asthma using mouse models. Ann Allergy Asthma Immunol 2001;87:96-109 (quiz 10).
Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999;160:594-9.
American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-18.
Hargreave FE, Sterk P, Adelroth EC, Ramsdale EH, O'Byrne PM. Airway responsiveness to histamine or methacholine: advances in measurement and interpretation. Respiration 1986;2:72-6.
Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993;16(Suppl):53-83.
Cockcroft DW. Airway responses to inhaled allergens. Can Respir J 1998;5(Suppl A):14A-7A.
Arshad SH. Bronchial allergen challenge: a model for chronic allergic asthma? Clin Exp Allergy 2000;30:12-5.
Bousquet J, Van-Cauwenberge P, Khaltaev N. Chairmen. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl):S1-125.
Crimi E, Spanevello A, Neri M, Ind PW, Rossi GA, Brusasco V. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am J Respir Crit Care Med 1998;157:4-9.
Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Br Med J 2001;323:253-6.
Stahl E. Correlation between objective measures of airway calibre and clinical symptoms in asthma: a systematic review of clinical studies. Respir Med 2000;94:735-41.
Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J 1999;14(1):23-7.
Juniper EF, O'Byrne PM, Ferrie PJ, King DR, Roberts JN. Measuring asthma control. Clinic questionnaire or daily diary? Am J Respir Crit Care Med 2000;162:1330-4.
Rutten-van-Molken MP, Custers F, van-Doorslaer EK, Jansen CC, Heurman L, Maesen FP, et al. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J 1995;8: 888-98.
Juniper EF. Quality of life in adults and children with asthma and rhinitis. Allergy 1997;52:971-7.
Jadad AR, Moher M, Browman GP, Booker L, Sigouin C, Fuentes M, et al. Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. Br Med J 2000;320:537-40.
Zanen P, Lammers JW. Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. Eur J Clin Pharmacol 1995;48:179 84.